BCBS of Alabama said the change continues its efforts to combat the opioid epidemic. Under the new policy, the health insurer’s commercial members will see other drugs covered instead of OxyContin. These include Roxybond, an instant-release oxycodone formulation that the Food and Drug Administration considers abuse deterrent, and Lucemyra, the first nonopioid drug approved to treat symptoms of opioid withdrawal.
In addition to OxyContin, BCBS of Alabama will also drop coverage for its generic oxycodone. Affected members have been notified of the change by mailed letters, and have several alternatives to choose from when it comes to long-acting opioids: morphine, tramadol, fentanyl and methadone.
More articles on opioids:
5 predictors of persistent opioid use among workers’ comp patients
FDA approves opioid 10 times stronger than fentanyl
Opioid use may up atrial fibrillation risk by 34%
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
